Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

Summary

This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer.

Conditions

• Cancer

Interventions

PROCEDURE

Bone scan

Scan to diagnose a number of bone conditions including cancer or metastasis

DRUG

99mTc-methyl diphosphonate

Radiolabel for bone scan procedures

PROCEDURE

Positron Emission Tomography (PET) scan

Scan to detect gamma rays emitted by a positron-emitting radioligand such as 18F

DRUG

18F-Fludeoxyglucose (18F-FDG)

Radiolabel for positron emission tomography scan procedures

PROCEDURE

Computed Tomography (CT) scan

Scan to detect \& analyze X-rays

DRUG

18F-Sodium Fluoride (18F-NaF)

Radiolabel for CT and PET scans, \& as a contrast agent for MRI scans.

PROCEDURE

Whole Body Magnetic Resonance Imaging (WB-MRI) scan

Whole Body Magnetic Resonance Imaging (WB-MRI) scan: Scan that uses strong magnetic fields \& radio waves to generate images of the organs in the body.

DRUG

Gadopentetate dimeglumine

A gadolinium-based contrast agent for MRI

DRUG

Gadofosveset

A gadolinium-based contrast agent for MRI

DRUG

Gadobutrol

A gadolinium-based contrast agent for MRI

Sponsors & Collaborators

• Stanford University

  lead OTHER

Principal Investigators

• Andrei Iagaru, MD · Stanford University

Study Design

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Model

SEQUENTIAL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2006-01-31

Primary Completion

2017-04-17

Completion

2019-03-14

FDA Drug

Yes

Countries

• United States

Study Locations